Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2026

The following table illustrates the timing of the Company’s revenue recognition patterns:


	Three Months Ended March 31,
	2026		2025
Software products and services – point in time	24.2	%	43.0	%
Software products and services – over time	36.5		32.5
Drug Discovery – point in time	—		2.1
Drug Discovery – over time	39.1		15.1
Contribution – point in time	—		—
Contribution – over time	0.2		7.3

The following table presents the revenue recognized from the sources of software products and services revenue:

The following table presents the revenue recognized from the sources of contribution revenue:


	Three Months Ended March 31,
	2026		2025
Software contribution	$	—	$	3,844
Drug discovery contribution	148		499
Total contribution revenue	$	148	$	4,343

Contract balances were as follows:


	As of March 31, 2026		As of December 31, 2025
Contract assets	$	19,196	$	19,698
Deferred revenue, short-term:
Software products and services	60,755		66,695
Drug discovery	42,356		46,027
Contribution	—		131
Deferred revenue, long-term:
Software products and services	6,202		7,333
Drug discovery	52,817		71,544
Contribution	—		—

Remaining performance obligations were as follows:


	As of March 31, 2026		As of December 31, 2025
Deferred revenue	Total			Total
Software products and services	$	66,957		$	74,028
Drug discovery	95,173			117,571
Contribution	—			131
Total deferred revenue	162,130			191,730
Backlog
Software products and services	31,630			31,036
Drug discovery	17,206			17,100
Contribution	—			—
Total backlog	48,836			48,136
Remaining performance obligations
Software products and services	98,587			105,064
Drug discovery	112,379			134,671
Contribution	—			131
Total remaining performance obligations	$	210,966		$	239,866